NEWARK, CA / ACCESSWIRE / January 29, 2024 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference being held in New York City on February 7-8, 2024.
Event: 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference Date: February 7-8, 2024
Presentation: Thursday, February 8 at 9:00-9:25 A.M. EST
Location: St. Regis New York, Two E. 55th Street, New York, NY 10022
A replay of the company presentation will be published to the Events & Presentations section of the Protagonist corporate website: https://www.protagonist-inc.com/events-presentations.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company’s proprietary peptide technology platform. Protagonist scientists jointly discovered oral peptide PN-235 (now known as JNJ-2113) as part of Protagonist’s Interleukin-23 receptor (IL-23R) collaboration with Johnson & Johnson and followed it through IND-enabling pre-clinical and Phase 1 studies, with Johnson & Johnson assuming responsibility for further clinical development. Rusfertide, a peptide-mimetic of the natural hormone hepcidin, is the Company’s lead drug candidate currently in a global Phase 3 development program. The randomized portion of the Phase 2 REVIVE study was unblinded, showing positive results and is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Protagonist retains all worldwide development and commercialization rights to rusfertide.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061
SOURCE: Protagonist Therapeutics, Inc.
View the original press release on accesswire.com
AMSTERDAM, June 26, 2025 /PRNewswire/ -- Vinamilk, Vietnam's leading dairy company, presented its science-driven innovation…
In the study of rare diseases and precision medicine, understanding gene expression in the spatial…
ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- A new survey of 195 diagnostic imaging and…
FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new…
TORRINGTON, Conn., June 26, 2025 /PRNewswire/ -- Therap Services, the leading provider of HIPAA-compliant electronic documentation…
Cutting-edge tool aims to enhance patient education and experience while improving operational efficiency LOS ANGELES,…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
